Pregled bibliografske jedinice broj: 916428
Hepatitis B and C serological profiles of liver/kidney donors and recipients: 10-year Croatian single centre analysis
Hepatitis B and C serological profiles of liver/kidney donors and recipients: 10-year Croatian single centre analysis // Transplant International
Barcelona, Španjolska, 2017. str. 435-435 (poster, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 916428 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Hepatitis B and C serological profiles of liver/kidney donors and recipients: 10-year Croatian single centre analysis
Autori
Mrzljak, Anna ; Dinjar Kujundzic, Petra ; Gardijan, Bojana ; Miletic, Manuela ; Ostojic, Ana ; Kosuta, Iva ; Mikulic, Danko ; Knotek, Mladen
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
Transplant International
/ - , 2017, 435-435
Skup
18th Cogress of the European Society for Organ Transplantation (ESOT)
Mjesto i datum
Barcelona, Španjolska, 24.09.2017. - 27.09.2017
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
liver/kidney transplantation ; seroprevalence of HBV and HCV in organ donors and recipients
Sažetak
Introduction: Screening for hepatitis B (HBV) and hepatitis C (HCV) viruses is a requirement in organ transplantation. The information acquired influences organ allocation and post-transplant management. The goal of this review was to determine HBV and HCV serological profiles of liver and kidney donors and recipients. Methods: HBV and HCV serologies were retrospectively obtained for adult liver and kidney recipients and their donors between 6/2006 and 6/2016 using a hospital transplant database. Results: In total 1308 serological profiles of organ recipients and their donors were analyzed. There were 452 kidney (65% male, mean age 49.5 _12.5 years.) and 856 liver recipients (72% male, mean age 55.1 _ 10.4 years). 1.5% kidney and 5.4% liver recipients were hepatitis B surface antigen (HBsAg) positive. 34.5% of kidney and 69.7% of liver recipients were non-immune to HBV. The prevalence of successful pre-transplant HBV vaccine immunity was greater in kidney than in liver recipients (36.9% vs 5.5%). 2.2% of kidney and 3.4% of liver recipients were only HBcAb positive. HBV vaccine immunity of both organ recipient groups did not change significantly during period of 10 years (p = ns). There were 2.2% kidney and 15.7% liver HCV antibody positive recipients. 1.1% of kidney and 0.2% of liver recipients were both HBsAg and HCVAb positive. From the total number of kidney grafts, 8.85% were HBcAb positive and no kidney grafts were HBsAg or anti-HCV positive. From the total number of liver grafts 7.7% were HBcAb, 0.1% HBsAg and 0.2% HCVAb positive. Conclusion: The prevalence of HBV and HCV HBV co-infection in organ recipients is low, as well as the prevalence of anti-HCV in kidney patients at the time of transplant. HBV immunity in the pre-transplant liver kidney cohort is low and has not changed significantly in the observed period. This analysis indicates that greater efforts should be implemented in the pre-transplant vaccination process.
Izvorni jezik
Engleski
POVEZANOST RADA
Profili:
Bojana Gardijan
(autor)
Danko Mikulić
(autor)
Manuela Miletić
(autor)
Anna Mrzljak
(autor)
Ana Ostojić
(autor)
Iva Košuta
(autor)
Mladen Knotek
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE